Banque Transatlantique SA Has $2.67 Million Stake in Edwards Lifesciences Corporation $EW

Banque Transatlantique SA reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 16.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,301 shares of the medical research company’s stock after selling 6,133 shares during the quarter. Banque Transatlantique SA’s holdings in Edwards Lifesciences were worth $2,668,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. MidFirst Bank bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $298,000. Kera Capital Partners Inc. boosted its position in Edwards Lifesciences by 8.8% during the 4th quarter. Kera Capital Partners Inc. now owns 6,006 shares of the medical research company’s stock worth $489,000 after acquiring an additional 488 shares during the last quarter. MV Capital Management Inc. acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $26,000. Compound Planning Inc. grew its stake in shares of Edwards Lifesciences by 20.9% during the 4th quarter. Compound Planning Inc. now owns 3,921 shares of the medical research company’s stock worth $334,000 after acquiring an additional 678 shares in the last quarter. Finally, Harbour Wealth Management Group Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $237,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $87.51 on Friday. The company has a fifty day moving average price of $83.27 and a two-hundred day moving average price of $83.11. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $89.60. The stock has a market cap of $50.39 billion, a P/E ratio of 46.55, a P/E/G ratio of 2.17 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the firm earned $0.64 EPS. Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Finally, Evercore restated an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 81,038 shares of company stock valued at $6,683,255. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.